TABLE 4.
Regression analysis of the relationship between APOE ε4/ε4 genotype and presence of AMB with comorbid neuropathological substrates in HAD
Predictors | Odds Ratio (95% CI) |
P value |
---|---|---|
HAD females | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.923 (1.175-3.149) |
0.009 |
HAD males | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.653 (1.108-2.465) |
0.014 |
HAD with LB | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 2.390 (1.535-3.722) |
0.001 |
HAD with LB, females | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 2.870 (1.412-5.834) |
0.004 |
HAD with LB, males | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 2.136 (1.208-3.775) |
0.009 |
HAD without LB | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.269 (0.810-1.987) |
0.298 |
HAD without LB, females | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.405 (0.692-2.852) |
0.347 |
HAD without LB, males | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.225 (0.683-2.197) |
0.497 |
HAD with CAA | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.826 (1.306-2.552) |
0.001 |
HAD with CAA, females | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.835 (1.075-3.131) |
0.026 |
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.809 (1.176-2.781) |
0.007 |
HAD without CAA | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 1.129 (0.417-3.052) |
0.811 |
HAD without CAA, females | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 3.300 (0.633-17.211) |
0.157 |
HAD without CAA, males | ||
No ε4 & ε4 (indicator) | ||
ε4/ε4 | 0.585 (0.155-2.212) |
0.430 |
Table representing LB and CAA’s impact as separate comorbid neuropathological substrates on the relationship between APOE4 and AMB in HAD. Predictors referred to presence of two (ε4/ε4) copies of the ε4 allele of the APOE gene in HAD cases with or without Lewy Bodies (LB), as well as with or without Cerebral Amyloid Angiopathy (CCA). Numerical values within each column represent Odds Ratio (OR) with associated 95% Confidence Interval (95% CI) and p value. The relationship between APOE4 genotype and AMB prevalence was assessed in an unadjusted logistic regression model.